Telix Pharmaceuticals (ASX:TLX) has announced that the US FDA has accepted its Biologics License Application for its breakthrough investigational kidney cancer PET imaging agent TLX250-CDx (Zircaix, 89ZrDFO-girentuximab).
US FDA accepts application for Telix's Zircaix and grants priority review
February 26, 2025 Australian Biotech
Latest Video
New Stories
-
New Zealand's Medsafe and Pharmac directed to explore AI use to expedite access
July 2, 2025 - - Latest News -
New treatment option for early breast cancer at high risk of recurrence
July 2, 2025 - - Latest News -
Expanded listing for Bristol Myers Squibb's PD-1 to include bladder cancer
July 2, 2025 - - Latest News -
The industry backs productivity focus for the Albanese Government's second term
July 2, 2025 - - Latest News -
Wesfarmers Health launches pilot pharmacy format, InstantScripts Pharmacy Health Hub
July 2, 2025 - - Latest News -
Moderna announces positive Phase 3 result for influenza vaccine
July 1, 2025 - - Latest News -
Takeda therapy now available through the PBS for serious viral infection
July 1, 2025 - - Latest News